Ritter Pharmaceuticals Reports First Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ritter Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update

LOS ANGELES, CA--(Marketwired - May 9, 2016) - Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a pharmaceutical company developing novel human gut microbiome therapeutic products to treat gastrointestinal diseases, today reported financial results and a business update for the first quarter ended March 31, 2016.

"During the first quarter we continued to execute on our business strategy and work toward completing our adaptive design phase 2b/3 clinical study of our lead product candidate, RP-G28, for treatment of lactose intolerance. We are pleased to report that the study is underway and is enrolling as expected. We believe that RP-G28 represents a significant commercial opportunity, as the current lactose intolerance product market has been estimated to be approximately $2.45 billion in the United States alone, and there is currently no durable FDA-approved treatment for lactose intolerance. On a global basis, studies have suggested that there are over one billion people who suffer from this condition, demonstrating the significant need for an effective and durable treatment. With an experienced management team, as well as a scientific advisory board comprised of top researchers in the fields of microbiology, nutrition and gastroenterology, we believe Ritter Pharmaceuticals is well positioned as we continue enrollment of our clinical trial and anticipate full enrollment by Q3 this year," said Michael D. Step, Chief Executive Officer of Ritter Pharmaceuticals.

Andrew Ritter, President of Ritter Pharmaceuticals, added, "It is exciting to see RP-G28 enrolling in a larger late-stage clinical trial and one step closer to market. RP-G28 has the novel ability to treat lactose intolerance by modulating the gut microbiome, and we believe that lactose intolerance is just one of many indications we could affect through this safe microbiome adaptation. Following our Phase 2a clinical trial, which demonstrated both safety and efficacy, as well as durable shifts in the microbiomes of treated patients, we have confidence in our Phase 2b/3 trial and we look forward to demonstrating an effective treatment for this large patient population."

First Quarter 2016 Financial Results

For the first quarter of 2016, Ritter Pharmaceuticals reported a net loss attributable to common stockholders of approximately $3.1 million compared to a net loss of approximately $1.6 million for the first quarter of 2015. Basic and diluted net loss per share was $0.36 for the first quarter of 2016 compared to basic and diluted net loss per share of $3.37 for the first quarter of 2015.

Research and development expenses totaled approximately $1.9 million for the first quarter of 2016 versus approximately $31,000 for first quarter of 2015. This increase was driven by the preparation of our adaptive design Phase 2b/3 clinical trial, which was initiated in March 2016.

General and administrative expenses for the first quarter of 2016 were approximately $1.2 million, compared to approximately $1.3 million for the first quarter of 2015.

Total operating expenses for the first quarter of 2016 were approximately $3.2 million compared to approximately $1.4 million for the first quarter of 2015.

As of March 31, 2016, Ritter Pharmaceuticals had cash and cash equivalents of approximately $14.1 million.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.

Forward-Looking Statements

This release may contain forward-looking statements, which express the current beliefs and expectations of Ritter Pharmaceuticals' management. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such statements involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the drug development process generally, including the outcomes of planned clinical trials and the regulatory review process; risks associated with obtaining, maintaining and protecting intellectual property; risk associated with Ritter Pharmaceuticals' ability to manage operating expenses and/or obtain additional funding to support its business activities; and risks associated with Ritter Pharmaceuticals' dependence on third parties. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

 
RITTER PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS
 
 
    March 31,   December 31, 
    2016    2015 
    (unaudited)     
ASSETS                
Current assets                
  Cash and cash equivalents   $ 14,088,541     $ 15,819,566  
  Prepaid expenses     144,005       189,136  
    Total current assets     14,232,546       16,008,702  
                 
Other assets     10,326       10,326  
Property and equipment, net     26,866       20,688  
    Total Assets   $ 14,269,738     $ 16,039,716  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities                
  Accounts payable   $ 2,128,065     $ 739,357  
  Accrued expenses     204,178       614,141  
  Other liabilities     1,223       1,223  
    Total current liabilities     2,333,466       1,354,721  
                 
Stockholders' equity                
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2016 and December 31, 2015     --       --  
Common stock, $0.001 par value; 25,000,000 shares authorized as of March 31, 2016 and December 31, 2015; 8,584,661 and 8,582,004 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively     8,585       8,582  
Additional paid-in capital     42,139,079       41,759,355  
Accumulated deficit     (30,211,392 )     (27,082,942 )
    Total stockholders' equity     11,936,272       14,684,995  
                 
    Total Liabilities and Stockholders' Equity   $ 14,269,738     $ 16,039,716  
                 
 
RITTER PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
 
    For the Three Months Ended March 31,  
    2016     2015  
Operating costs and expenses                
  Research and development   $ 1,882,848     $ 31,460  
  Patent costs     32,364       62,274  
  General and administrative     1,235,018       1,302,565  
    Total operating costs and expenses     3,150,230       1,396,299  
                 
Operating loss     (3,150,230 )     (1,396,299 )
                 
Other income                
  Interest income     20,566       2,204  
  Other income     1,214       7,091  
    Total other income     21,780       9,295  
                 
    Net loss   $ (3,128,450 )   $ (1,387,004 )
                 
Cumulative preferred stock dividends     --       (149,283 )
Accretion of discount of Series C preferred stock     --       (31,818 )
                 
    Net loss attributable to common stockholders   $ (3,128,450 )   $ (1,568,105 )
                 
Net loss attributable to common stockholders per share, basic and diluted   $ (0.36 )   $ (3.37 )
                 
Weighted average shares outstanding, basic and diluted     8,583,259       465,384  
                 

Contacts Investor Contact: David Burke dburke@theruthgroup.com (646) 536-7009 Media Contact: Chris Hippolyte chippolyte@theruthgroup.com 646.536.7023

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading